

Pfizer Australia Pty Ltd
ABN: 50 008 422 348
Level 17, 151 Clarence Street
Sydney, NSW, 2000

20th August 2025

Dear Healthcare Professional,

**PRODUCT AVAILABILITY UPDATE FOR:
BICILLIN L-A benzathine benzylpenicillin tetrahydrate 1,200,000 units/2.3 mL suspension for injection
syringe with needle [ARTG 147169]**

Following our communication on 28th July, Pfizer Australia would like to provide an update regarding the stock availability of Bicillin L-A benzathine benzylpenicillin tetrahydrate 1,200,000 units/2.3 mL suspension for injection ARTG [147169].

Presentation	Pack Size	Pfizer Item Code	Estimated Wholesaler Out of Stock Date	Estimated Back in Stock Date at Wholesalers
Bicillin L-A benzathine benzylpenicillin tetrahydrate 1,200,000 units/2.3 mL suspension for injection [ARTG 147169]	10 vials	PF_F000156028	NOW	Mid September 2025

We are pleased to share that the recent batch manufactured has already been released. The shipment is scheduled to depart on 22nd August, estimated to arrive SYD on 25th August and this should cover for 2.5 months of normal demand.

Pfizer will communicate further planned batch delivery in late September, which we anticipate will resolve the current shortage.

We understand and regret the challenges that this situation poses to patients. Pfizer fully realises the importance of this medicine to patients. We thank you for your understanding and apologise for any inconvenience caused to you and your patients. Pfizer is working diligently to minimise patient impact and resolve the disruption in supply. Pfizer will provide updates as appropriate to keep you informed on this situation.

The reason for this temporary interruption in supply does not impact the quality, safety or efficacy of the finished product already on the market.

Alternate suppliers, including Orspec Pharma, may have potential therapeutic alternatives. Orspec Pharma can be contacted on: Ph: +61 2 4339 4239 or e-mail: customerservice@orspecpharma.com.

Complete information regarding the approved indications for Bicillin L-A (benzathine benzylpenicillin tetrahydrate 1,200,000 units/2.3 mL suspension for injection) can be found in the Product Information available at <https://www.tga.gov.au/>.

Please direct all medical enquiries regarding for Bicillin L-A to Pfizer Medical Information on 1800 675 229 from 9am-5pm AEDT, Mon-Fri or via www.pfizermedicalinformation.com.au for assistance.

Should you have any enquiry on stock availability, please contact Pfizer Customer Service on 1800 629 921.

Adverse Event Reporting

Reporting of suspected adverse events is important for the monitoring of the safety of all medicines. Any adverse events which are experienced with these products should be reported by healthcare professionals and/or patients to the TGA via <http://www.tga.gov.au/reporting-problems> or to Pfizer on 1800 675 229 or by email to AUS.AEReporting@pfizer.com

Yours sincerely,



Myleen Cu

Commercial Supply Manager - Hospital Business Unit
Pfizer Australia and New Zealand